Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and renewed merger activity pulled capital back into a sector that spent much of the prior cycle in drawdown. The three ETFs below offer distinct ways to participate: one anchors a portfolio in profitable incumbents, one tilts toward the small- and mid-cap names that carry the binary upside, and one is a short-duration trading instrument for directional bets.
iShares Biotechnology ETF: The Large-Cap Anchor
The iShares Biotechnology ETF (NASDAQ:IBB | IBB Price Prediction) is the default large-cap vehicle for the sector. It is market-cap weighted, which concentrates the fund in cash-generative incumbents rather than spreading capital across clinical-stage names. The top four positions, Gilead Sciences at about 7%, Amgen at roughly 7%, Vertex Pharmaceuticals near 7%, and Regeneron around 6%, together account for close to a third of the portfolio, per the iShares IBB fund fact sheet.
The investment logic is exposure to biotech innovation without the full binary risk profile of early-stage drug development. These companies already have approved franchises, recurring revenue, and balance sheet capacity to acquire smaller peers. Biotechnology accounts for about 89% of the sector weight, with life sciences tools and pharmaceuticals rounding out the remainder, preserving thematic purity even with the blue-chip tilt.
IBB has returned about 45% over the past year and carries $8.12 billion in net assets, making it one of the deepest and most liquid biotech funds available. The ETF was launched in February 2001, giving it the longest track record in the category.
The tradeoff is concentration at the top. When a single large holding stumbles on a pipeline setback or a patent headline, the fund feels it is more than an equal-weight alternative would be. Investors looking for diversified exposure to small-cap catalysts will find IBB too top-heavy for that purpose.
SPDR S&P Biotech ETF: Equal-Weight Exposure to the Small-Cap Tail
The SPDR S&P Biotech ETF (NYSEARCA:XBI) is built on a different premise. According to the State Street SPDR XBI factsheet, it tracks a modified equal-weight version of the S&P Biotechnology Select Industry Index, which means a $20 billion biotech and a $2 billion clinical-stage company receive similar portfolio allocations at rebalance. The result is a fund where the top holdings sit at roughly 1% to 2% each, with names like Apellis Pharmaceuticals near 2%, Alkermes around 1%, and Madrigal Pharmaceuticals around 1%, leading a roster of 155 holdings.
This methodology is the reason XBI is the preferred vehicle for capturing biotech’s asymmetric upside. Clinical readouts, FDA decisions, and takeout premiums tend to land on smaller companies, and an equal-weight structure gives those events meaningful influence on the fund’s return. The same mechanism works in reverse on failed trials, which is the source of XBI’s higher volatility relative to IBB.
The one-year return of about 77% versus IBB’s roughly 45% over the same window reflects the payoff profile in an up cycle for small and mid-cap biotech. Over the trailing five years, XBI has returned about 2%, a reminder that the equal-weight tilt produces extended drawdowns when small-cap sentiment turns. Composite sentiment from our internal model reads bullish with a score of 68.1, driven largely by social and news components.
The caveat is the volatility profile as an equal-weight small-cap biotech fund moves harder in both directions than a market-cap-weighted peer. Investors who cannot tolerate 30% or more peak-to-trough swings within a single cycle may find XBI uncomfortable even when the long-term thesis plays out.
Direxion Daily S&P Biotech Bull 3X Shares: Tactical Amplifier
The Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) seeks three times the daily return of the same S&P Biotechnology Select Industry Index that XBI tracks. The fund is built for short holding periods. Its exposure resets each day, and the compounding of daily returns over longer stretches means the fund’s path rarely resembles three times the index’s cumulative return.
The return history shows exactly what that means in practice. Over the past year, LABU returned roughly 338% as biotech rallied. Over the past five years, the same fund has returned about -86%, and over ten years, around -72%, despite XBI itself posting roughly 141% over the trailing decade. Volatility decay erodes leveraged funds during sideways, choppy markets, which are the default environment for biotech in most years.
The one-month gain of about 43% during a period when XBI gained roughly 13% illustrates how LABU is meant to be used. It works as an amplifier on a short directional view, measured in days or weeks rather than quarters.
The structural tradeoffs are explicit. Daily reset mechanics, path-dependent returns, higher carrying costs from the embedded swap exposure, and zero suitability as a long-term holding. The long-dated chart is the clearest reminder of what happens when leveraged products are held through a full cycle.
Choosing Between the Three
Investors looking for core biotech exposure with the profile of a diversified large-cap growth sleeve will find IBB the closest match. XBI suits allocations built around pipeline catalysts and takeout optionality, where the equal-weight construction is the point rather than a side effect. LABU is a tactical instrument for traders expressing a short-term directional view on the sector, built for short holding periods rather than as a core allocation.
Top Gaining Stocks
Top Losing Stocks